American Banking and Market News logo

The Latest Headlines at American Banking and Market News

Image about Wayfair Inc. (NYSE:W) Receives Average Recommendation of “Moderate Buy” from Analysts

Wayfair Inc. (NYSE:W) Receives Average Recommendation of “Moderate Buy” from Analysts

Wayfair Inc. (NYSE:W – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. Ten analysts have rated... More of this article »
Image about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twenty-five ratings firms that are presently covering the company, Marketbeat Ratings... More of this article »
Image about Texas Roadhouse, Inc. (NASDAQ:TXRH) Given Consensus Rating of “Moderate Buy” by Analysts

Texas Roadhouse, Inc. (NASDAQ:TXRH) Given Consensus Rating of “Moderate Buy” by Analysts

Texas Roadhouse, Inc. (NASDAQ:TXRH – Get Free Report) has earned an average rating of “Moderate Buy” from the eighteen ratings firms that are currently covering the firm, Marketbeat.com reports. Nine investment analysts... More of this article »
Image about Clarus Co. (NASDAQ:CLAR) Receives Consensus Rating of “Moderate Buy” from Analysts

Clarus Co. (NASDAQ:CLAR) Receives Consensus Rating of “Moderate Buy” from Analysts

Clarus Co. (NASDAQ:CLAR – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Two analysts have... More of this article »
Image about Physicians Realty Trust (NYSE:DOC) Receives Consensus Rating of “Hold” from Brokerages

Physicians Realty Trust (NYSE:DOC) Receives Consensus Rating of “Hold” from Brokerages

Physicians Realty Trust (NYSE:DOC – Get Free Report) has been assigned a consensus recommendation of “Hold” from the nine research firms that are currently covering the company, Marketbeat.com reports. One investment... More of this article »
Image about Booz Allen Hamilton Holding Co. (NYSE:BAH) Receives Consensus Recommendation of “Hold” from Analysts

Booz Allen Hamilton Holding Co. (NYSE:BAH) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Booz Allen Hamilton Holding Co. (NYSE:BAH – Get Free Report) have been given a consensus recommendation of “Hold” by the nine brokerages that are presently covering the firm, MarketBeat reports. One equities... More of this article »
Image about Varonis Systems’ (VRNS) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Varonis Systems’ (VRNS) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Varonis Systems (NASDAQ:VRNS – Free Report) in a research report sent to investors on Friday morning, Benzinga reports. The brokerage currently has a $56.00... More of this article »
Image about UroGen Pharma (NASDAQ:URGN) PT Lowered to $34.00 at Oppenheimer

UroGen Pharma (NASDAQ:URGN) PT Lowered to $34.00 at Oppenheimer

UroGen Pharma (NASDAQ:URGN – Free Report) had its price objective lowered by Oppenheimer from $35.00 to $34.00 in a research report released on Friday, Benzinga reports. The brokerage currently has an outperform rating on the... More of this article »
Image about Stifel Nicolaus Reaffirms Buy Rating for Viking Therapeutics (NASDAQ:VKTX)

Stifel Nicolaus Reaffirms Buy Rating for Viking Therapeutics (NASDAQ:VKTX)

Stifel Nicolaus reissued their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a research note published on Friday, Benzinga reports. The brokerage currently has a $80.00 price target on the biotechnology... More of this article »
Image about Verastem (NASDAQ:VSTM) Rating Reiterated by Royal Bank of Canada

Verastem (NASDAQ:VSTM) Rating Reiterated by Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Verastem (NASDAQ:VSTM – Free Report) in a report published on Friday morning, Benzinga reports. They currently have a $32.00 target price on the biopharmaceutical... More of this article »
Image about Viking Therapeutics’ (VKTX) “Buy” Rating Reiterated at HC Wainwright

Viking Therapeutics’ (VKTX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a research note released on Friday morning, Benzinga reports. They currently have a $90.00 price objective on the biotechnology... More of this article »
Image about Urgent.ly (NASDAQ:ULY) Price Target Cut to $5.00

Urgent.ly (NASDAQ:ULY) Price Target Cut to $5.00

Urgent.ly (NASDAQ:ULY – Free Report) had its price objective cut by Needham & Company LLC from $7.00 to $5.00 in a research note released on Friday, Benzinga reports. They currently have a buy rating on the stock. Urgent.ly... More of this article »
Image about CarGurus (NASDAQ:CARG) Price Target Raised to $27.00

CarGurus (NASDAQ:CARG) Price Target Raised to $27.00

CarGurus (NASDAQ:CARG – Free Report) had its target price raised by UBS Group from $26.00 to $27.00 in a report issued on Friday morning, Benzinga reports. The brokerage currently has a neutral rating on the stock. CARG has been... More of this article »
Image about AssetMark Financial Holdings, Inc. (NYSE:AMK) Short Interest Update

AssetMark Financial Holdings, Inc. (NYSE:AMK) Short Interest Update

AssetMark Financial Holdings, Inc. (NYSE:AMK – Get Free Report) was the target of a significant growth in short interest in February. As of February 29th, there was short interest totalling 254,500 shares, a growth of 11.4%... More of this article »
Image about Viking Therapeutics (NASDAQ:VKTX) Receives Buy Rating from Maxim Group

Viking Therapeutics (NASDAQ:VKTX) Receives Buy Rating from Maxim Group

Maxim Group reaffirmed their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a report issued on Friday, Benzinga reports. They currently have a $120.00 price target on the biotechnology company’s... More of this article »